Skip to main content

Table 1 Main baseline features of the patients enrolled in the study

From: Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy

Patient

Age

Sex

Primary tumour

Metastases

Previous therapy

1

76

M

Ileum NET

Liver

Octreotide, interferon alfa

2

62

M

Meningioma

None

None

3

61

M

Pancreatic NET

Local vessel infiltration

Stenting

4

82

F

Pancreatic NET

Liver, bone

Surgery

5

50

M

Rectal NET

Bone

Surgery

6

67

F

Liver NET

LN, muscle, brain

Surgery

7

69

M

Small bowel NET

Liver, lung, LN

None

8

50

F

Pancreatic NET

Liver, LN

Octreotide, everolimus, lanreotide

9

49

M

Small cell lung cancer

LN

CTx

10

73

F

Pancreatic NET

Bone, liver

Surgery

11

58

F

Ileum NET

Liver, LN

Surgery, octreotide, thermoablation

12

57

F

Carcinoid

Lung, bone

Surgery, RCTx

13

31

F

Medullary thyroid cancer

Lung, LN, bone

Surgery, CTx

14

24

M

Ileum NET

Liver

Surgery, TACE, octreotide

15

66

M

Thymus NET

Bone, lung, LN

None

16

60

F

Meningioma

None

Surgery

17

34

M

Paraganglioma

Bone

Surgery, RTx

18

61

M

Small bowel NET

Liver, LN

Surgery, octreotide

19

55

M

Pancreatic NET

Liver, LN

CTx

20

63

M

Pancreatic NET

LN, liver, bone

Surgery

21

68

F

Small bowel NET

Liver, LN

Surgery

22

54

M

Cerebral NET

Bone

CTx

  1. M male, F female, NET neuroendocrine tumour, LN lymph nodes, CTx chemotherapy, RCTx radiochemotherapy, TACE transcatheter arterial chemoembolization, RTx radiotherapy.